{"id":21375,"date":"2022-05-12T11:18:17","date_gmt":"2022-05-12T09:18:17","guid":{"rendered":"https:\/\/idibell.cat\/?p=21375"},"modified":"2022-05-12T11:19:11","modified_gmt":"2022-05-12T09:19:11","slug":"estableixen-un-nou-sistema-dedicio-genetica-en-animals","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/05\/estableixen-un-nou-sistema-dedicio-genetica-en-animals\/","title":{"rendered":"Estableixen un nou sistema d\u2019edici\u00f3 gen\u00e8tica en animals"},"content":{"rendered":"<p>Un equip d&#8217;investigadors de l&#8217;Institut de Recerca Biom\u00e8dica de Bellvitge (<a href=\"https:\/\/idibell.cat\/\">IDIBELL<\/a>) i del Centre Andal\u00fas de Biologia del Desenvolupament (<a href=\"http:\/\/www.cabd.es\/es\/\">CABD-CSIC<\/a>, UPO i JA) han posat a punt una nova variant de l&#8217;eina d&#8217;edici\u00f3 gen\u00e8tica CRISPR-Cas que permet modificar regions de gens fins ara inabastables.<\/p>\n<p>La tecnologia d&#8217;edici\u00f3 gen\u00e8tica amb CRISPR-Cas \u00e9s probablement una de les eines biotecnol\u00f2giques m\u00e9s revolucion\u00e0ries i amb m\u00e9s potencial descrites en els darrers anys. Aquesta eina utilitza una prote\u00efna (Cas) amb dos dominis: un que s&#8217;uneix espec\u00edficament a la seq\u00fc\u00e8ncia de l&#8217;ADN que es pret\u00e9n editar; i un altre, a mode de tisores moleculars, que permet modificar aquesta regi\u00f3.<\/p>\n<p>L&#8217;estudi publicat avui a la revista <a href=\"https:\/\/www.nature.com\/articles\/s41467-022-30228-4\"><strong><em>Nature Communications<\/em><\/strong><\/a> mostra per primera vegada en animals un nou sistema de CRISPR-Cas en qu\u00e8 <strong>s&#8217;ha modificat el domini de reconeixement de l&#8217;ADN per poder detectar nous llocs al genoma<\/strong>. Aquesta nova eina demostra ser efica\u00e7 i especifica en el model de cuc Caernorhabditis elegans i al peix zebra (zebrafish).<\/p>\n<p>El <strong>Dr. Juli\u00e1n Cer\u00f3n<\/strong>, cap grup a l&#8217;IDIBELL i col\u00edder del projecte juntament amb <strong>Miguel \u00c1ngel Moreno-Mateos<\/strong> del CABD, declara: &#8220;<em>Aquest nou sistema expandeix les possibilitats de l&#8217;edici\u00f3 gen\u00e8tica, podent arribar a moltes m\u00e9s zones del genoma fins ara molt dif\u00edcils de modificar<\/em>&#8220;.<\/p>\n<p>Per la seva banda, <strong>Jeremy Vicencio<\/strong>, investigador de l&#8217;IDIBELL i primer autor del treball juntament amb <strong>Carlos S\u00e1nchez-Bola\u00f1os<\/strong> del CABD, afirma que &#8220;<em>ha estat molt emocionant trobar les condicions en paral\u00b7lel en cucs i peixos on aquest nou CRISPR-Cas9 funcion\u00e9s tan b\u00e9<\/em>&#8220;.<\/p>\n<p>&nbsp;<\/p>\n<h3>Condicions per al seu funcionament en animals<\/h3>\n<p>La modificaci\u00f3 del domini de reconeixement de l&#8217;ADN d&#8217;aquest nou sistema millorat de CRISPR-Cas9 va ser ideat i executat per experts en estructura de prote\u00efnes del laboratori de Ben Kleinstiver a Boston, que tamb\u00e9 han participat en l&#8217;estudi. Fins ara, aquesta nova eina havia mostrat efic\u00e0cia en l\u00ednies cel\u00b7lulars i plantes, per\u00f2 no s&#8217;havia aconseguit aplicar en l&#8217;edici\u00f3 del genoma d&#8217;animals.<\/p>\n<p>En aquest treball, els laboratoris del Dr. Cer\u00f3n a IDIBELL i del Dr. Moreno-Mateo a CABD han unit forces per fer funcionar aquesta t\u00e8cnica en animals. Tot i que en un inici el nou CRISPR-Cas9 semblava no ser \u00fatil per al genoma animal, <strong>els investigadors van aconseguir fer-lo funcionar incrementant la seva concentraci\u00f3 fins a sis vegades<\/strong>.<\/p>\n<p>&#8220;<em>Encara que no ho sabem amb certesa, per\u00f2 \u00e9s possible que la necessitat d&#8217;incrementar la concentraci\u00f3 sigui deguda al fet que aquest nou sistema t\u00e9 m\u00e9s potencials dianes d&#8217;acci\u00f3 i, per tant, necessiti m\u00e9s prote\u00efnes Cas9 que busquin en lloc adequat<\/em> -comenta el <strong>Dr. Cer\u00f3n<\/strong>-. <em>Tot i aix\u00ed, malgrat l&#8217;elevada concentraci\u00f3, hem demostrat que \u00e9s igual d&#8217;espec\u00edfic que l&#8217;anterior<\/em>&#8220;.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aquesta nova eina de CRISPR-Cas9 \u00e9s capa\u00e7 de modificar regions de gens inaccessibles fins ara, expandint enormement les possibilitats de l&#8217;edici\u00f3 gen\u00e8tica i de la medicina de precisi\u00f3.<\/p>\n","protected":false},"author":8,"featured_media":21376,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[334,355,464],"tags":[],"class_list":["post-21375","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-translacional","category-models-de-malaltia-en-c-elegans","category-p-de-gens-malaltia-i-terapia"],"publishpress_future_action":{"enabled":false,"date":"2025-03-02 11:45:54","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=21375"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21375\/revisions"}],"predecessor-version":[{"id":21378,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21375\/revisions\/21378"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/21376"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=21375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=21375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=21375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}